RT Journal Article SR Electronic T1 Trihexyphenidyl Interactions with the Dopamine D1-Selective Receptor Agonist SKF-82958 and the D2-Selective Receptor Agonist N-0923 in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Hemiparkinsonian Monkeys JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 307 OP 311 VO 284 IS 1 A1 Edward F. Domino A1 Lisong Ni YR 1998 UL http://jpet.aspetjournals.org/content/284/1/307.abstract AB The effects of the antiparkinsonian agent trihexyphenidyl, a selective M1 muscarinic cholinergic receptor antagonist, were studied in doses of 100, 320 and 1000 μg/kg i.m. alone. Trihexyphenidyl was then studied in combination with the selective dopamine receptor D1 agonist SKF-82958 [(±)-6-chloro-7–8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzazepine hydrobromide] and the selective D2 agonist N-0923 [(−)2-(N-propyl-N-2-thienylethyl)amino-5-hydroxytetralin HCl] on rotational behavior in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned hemiparkinsonian monkeys. Given alone, trihexyphenidyl had no effect on ipsiversive and slightly enhanced contraversive circling. Contraversive circling produced by 74.8 and 234 μg/kg SKF-82958 i.m. was potentiated by increasing doses of trihexyphenidyl. On the other hand, contraversive circling produced by 10 and 32 μg/kg N-0923 i.m. was progressively reduced with increasing doses of trihexyphenidyl. The results obtained indicate differential actions on circling behavior between a selective M1 muscarinic cholinergic receptor antagonist and selective D1 and D2 receptor agonists in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkey model of hemiparkinsonism. The American Society for Pharmacology and Experimental Therapeutics